# Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant

> **NCT05712265** · PHASE1 · COMPLETED · sponsor: **Corcept Therapeutics** · enrollment: 26 (actual)

## Conditions studied

- Antipsychotic Induced Weight Gain
- Non-alcoholic Steatohepatitis (NASH)

## Interventions

- **DRUG:** Miricorilant
- **DRUG:** Fluvoxamine

## Key facts

- **NCT ID:** NCT05712265
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-24
- **Primary completion:** 2023-02-23
- **Final completion:** 2023-02-23
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2023-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05712265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05712265, "Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05712265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*